A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
This phase 2 clinical trial will investigate an optimal dose, dosing regimen, and evaluate reactogenicity, safety and immunogenicity in healthy adult participants of the recombinant, multivalent MVA-BN-WEV vaccine. MVA-BN-WEV is intended for active immunization for prevention of disease induced by VEEV and EEEV, in persons aged 18 years and older at high risk of exposure.
Epistemonikos ID: 7fc8ce6e4d0bfb4374be2e79d42d2dbdfb1afc57
First added on: Mar 29, 2025